SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension

NCT06804161 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

3000

Enrollment

OTHER

Sponsor class

Conditions

Atrial Hypertension

Interventions

DRUG: SGLT2
DRUG: Placebo

Sponsor

Prof. Dr. med. Ingo Eitel